West Pharmaceutical Services, Inc. (NYSE:WST) had its price target lifted by Wells Fargo & Company from $105.00 to $112.00 in a research note issued to investors on Friday, October 27th. They currently have an outperform rating on the medical instruments supplier’s stock.
WST has been the subject of a number of other research reports. Stephens assumed coverage on shares of West Pharmaceutical Services in a report on Tuesday, October 3rd. They issued an equal weight rating and a $99.00 target price for the company. Zacks Investment Research cut shares of West Pharmaceutical Services from a buy rating to a hold rating in a report on Tuesday, July 4th. BidaskClub downgraded West Pharmaceutical Services from a hold rating to a sell rating in a research note on Thursday, July 27th. Bank of America Corporation downgraded West Pharmaceutical Services from a buy rating to a neutral rating and set a $98.00 price objective for the company. in a research note on Tuesday, October 17th. Finally, Jefferies Group LLC raised West Pharmaceutical Services from a hold rating to a buy rating and upped their price objective for the company from $96.00 to $115.00 in a research note on Friday, September 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. West Pharmaceutical Services presently has an average rating of Hold and an average price target of $106.00.
West Pharmaceutical Services (NYSE WST) traded down $0.78 on Friday, reaching $100.85. 282,200 shares of the company traded hands, compared to its average volume of 366,456. West Pharmaceutical Services has a 1-year low of $76.89 and a 1-year high of $103.36. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.59 and a quick ratio of 1.87. The company has a market capitalization of $7,546.32, a PE ratio of 43.81, a price-to-earnings-growth ratio of 2.17 and a beta of 1.14.
West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.14. The business had revenue of $398.20 million during the quarter, compared to analysts’ expectations of $386.02 million. West Pharmaceutical Services had a net margin of 12.12% and a return on equity of 14.47%. West Pharmaceutical Services’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.53 earnings per share. sell-side analysts anticipate that West Pharmaceutical Services will post 2.76 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in WST. Acrospire Investment Management LLC acquired a new stake in West Pharmaceutical Services during the 2nd quarter valued at approximately $113,000. Citigroup Inc. grew its position in shares of West Pharmaceutical Services by 95.1% during the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 765 shares during the period. Wolverine Trading LLC acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $200,000. Nomura Holdings Inc. acquired a new stake in shares of West Pharmaceutical Services during the 2nd quarter worth approximately $201,000. Finally, Grandfield & Dodd LLC acquired a new stake in shares of West Pharmaceutical Services during the 3rd quarter worth approximately $201,000. 91.02% of the stock is owned by institutional investors and hedge funds.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with our FREE daily email newsletter.